MINNEAPOLIS, Oct. 6 /PRNewswire-FirstCall/ --
Uroplasty, Inc. (AMEX:UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today highlighted presentations, workshops and posters focused on its products at the 39th Annual Meeting of the International Continence Society Meeting (ICS), September 29 - October 3 in San Francisco.
Both Uroplasty's Urgent® PC and Macroplastique® were highlighted. Urgent® PC presentations and posters included:
-- "Six and 12 Month Results from OrBIT Trial Comparing Percutaneous
Tibial Nerve Stimulation (PTNS) vs. Extended-Release Tolterodine," a
poster presentation by Kenneth M. Peters, M.D., Chairman of the
Department of Urology at Beaumont Hospital in Royal Oak, Mich.,
demonstrated Urgent® PC has comparable performance to the leading
prescribed overactive bladder drug and excellent durability through 12
months of follow-up. To assess the longer term effectiveness of Urgent
PC, 30 and 25 patients in the OrBIT study completed voiding diaries at
6 and 12 months respectively. The patients showed sustained
improvement with self-assessment of 93.8 percent improvement at 6
months and 96 percent at 12 months. Investigators' assessments of
improvement were similar, 96.9 percent and 96 percent. There were no
serious adverse events or device malfunctions.
-- "Percutaneous Tibial Nerve Stimulation: Efficacy with Patients also
Taking Anticholinergics," a poster presented by Leslie Wooldridge,
GNP, of Mercy Health Partners Bladder Control Clinic, Muskegon,
Mich., found Urgent PC to be an effective adjunct to anticholinergic
medications or replacement for medications used to treat overactive
bladder symptoms.
-- "Is Cost the Achilles Heel of Posterior Tibial Nerve Stimulation? A
Cost Minimisation Comparison with Antimuscarinic Therapy in the
Management of OAB," a poster presented by Dudley Robinson, M.D., of
King's College Hospital in London, England, suggesting that while drug
therapy is initially less expensive than Urgent PC, there is a trend
to reduced costs in Urgent PC over time as the initial equipment costs
are offset, suggesting that therapy may become increasingly cost
effective over the long term.
Urgent PC was highlighted in workshops entitled:
-- "Update on the Management of Overactive Bladder Syndrome," chaired by
Hashim Hashim, M.D., Bristol Urological Institute, Bristol, England
-- "Treatment of LUT Dysfunction by Means of Electrical Stimulation:
Scientific Foundation and Clinical Applications," chaired by John
Heesakkers, M.D. of Radboud University Nijmegen, The Netherlands.
"The clinical data presented at the 2009 Annual ICS Meeting continues to add to the existing body of clinical evidence from leading physicians highlighting the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms associated with overactive bladder," said David Kaysen, President and CEO of Uroplasty, Inc. "This represents still further data that we will present to the medical directors of U.S. payers as part of our ongoing effort to continue to build awareness for reimbursement and apply for a unique CPT code for PTNS here in the U.S. In addition to Urgent PC, Macroplastique, our 'Gold Standard' bulking agent for the treatment of adult female stress urinary incontinence received attention and is continuing to find a larger and larger receptive audience."
Several Macroplastique presentations were also made at the ICS annual meeting:
-- "Redefining the Success Rate of Bulking Agents: Role of Composite
Endpoints," a poster by Arasee Renganathan, M.D. of King's College
Hospital in London, England, which found 80 percent of women
considered themselves cured with Macroplastique and 75 percent were
considered cured by objective standards.
In addition to this presentation, Macroplastique was highlighted in workshops entitled:
-- "Practical Aspects of Bulking Agents in the Treatment of Pelvic Floor
Dysfunction," chaired by Sherif Mourad, M.D. of Ain Shams University,
Cairo, Egypt.
-- "Urethal Bulking Agents for the Minimally Invasive Treatment of Stress
Urinary Incontinence," chaired by Linda Cardozo, M.D. of King's
College Hospital in London, England.
"The 39th Annual ICS Meeting represents another significant success for Uroplasty," concluded Mr. Kaysen. "Urgent PC and Macroplastique were the subject of numerous positive discussions in diverse venues. These presentations resulted in enhanced interest in our products that resulted in more physician visits to our exhibit booth in turn generating a large number of sales leads."
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent® PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB). We also offer Macroplastique® Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com/.
Forward-Looking Information
This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT reimbursement code from the AMA for Urgent PC treatments, and that even if we succeed at obtaining a CPT code third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses. We further cannot assure that reimbursement or other issues will not further impact our fiscal 2010 results.
For Further Information:
Uroplasty, Inc. EVC Group
David Kaysen, President and CEO, or Doug Sherk (Investors)
Medi Jiwani, Vice President, CFO, 415.896.6820
and Treasurer, Chris Gale (Media)
952.426.6140 646.201.5431
DATASOURCE: Uroplasty, Inc.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice
President, CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or
Investors, Doug Sherk, +1-415-896-6820, or Media, Chris Gale, +1-646-201-5431,
both of EVC Group, for Uroplasty, Inc.
Web Site: http://www.uroplasty.com/